On August 14, Core Scientific, Inc. fell 5.03% in regular trading, trading at $19.85 per share, with turnover of approximately $128 million.

The decline follows a brief technical rebound on August 11-12 that failed to sustain momentum. The company previously reported Q2 net loss of $3.32 per share, far exceeding analyst expectations of a $0.06-$0.10 loss, despite revenue of $164.2 million beating estimates. The massive earnings shortfall continues to weigh heavily on market confidence.

Additionally, the AMD partnership announced in late July, which provides up to 2.5 gigawatts of data center capacity, includes market-priced warrants allowing AMD to purchase Core Scientific shares, raising ongoing dilution concerns among investors. While B. Riley raised its target price to $42 maintaining a Buy rating, and Keefe Bruyette upgraded to Outperform with a $28 target, the combination of deep quarterly losses and equity dilution pressure has overwhelmed bullish analyst sentiment, driving renewed selling.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)